{"id":230256,"date":"2026-09-04T09:37:52","date_gmt":"2026-09-04T04:07:52","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=230256"},"modified":"2026-09-04T09:37:53","modified_gmt":"2026-09-04T04:07:53","slug":"is-gland-pharma-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-gland-pharma-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Gland Pharma a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"
<\/div>\n

Gland Pharma share price around Rs 2,821. 7.2% below 52-week high of Rs 3,039. Q1 FY27 revenue Rs 1,800 crore, up 19.6% YoY. PAT Rs 317 crore, up 47.1%. PE 33x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Gland Pharma’s Q1 FY27 results were strong, with revenue at Rs 1,800 crore and PAT climbing 47% to Rs 317 crore. The Gland Pharma share price near Rs 2,821 reflects that optimism, so investors weighing whether Gland Pharma is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.<\/p>\n<\/div>\n

The Gland Pharma share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Gland Pharma is an injectable pharmaceutical manufacturer with a growing contract development and manufacturing (CDMO) business, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 1,800 crore, up 19.6% year on year, while profit after tax came in at Rs 317 crore, up 47.1% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Gland Pharma share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Gland Pharma share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n